<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01816321</url>
  </required_header>
  <id_info>
    <org_study_id>143201316398</org_study_id>
    <secondary_id>2013-000583-29</secondary_id>
    <nct_id>NCT01816321</nct_id>
  </id_info>
  <brief_title>Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial</brief_title>
  <acronym>COMPORT</acronym>
  <official_title>Corifollitropin Alfa Followed by Hp-HMG Versus Recombinant FSH in Young Poor Ovarian Responders. A Multicentre Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ho Chi Minh City University of Medicine and Pharmacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In combination with the existing literature, previous work indicates that 1) women with poor
      ovarian response fulfilling the &quot;Bologna criteria&quot; have very low pregnancy rates,
      irrespective of age 2) current treatment protocols demonstrate ongoing pregnancy rates that
      do not exceed 8.5% and 3) corifollitropin alfa followed by hpHMG might increase ongoing
      pregnancy rates in young patients (&lt;40years old) fulfilling the criteria. These findings
      provide a strong rationale for a definitive large RCT. The COMPORT study will provide
      conclusive evidence regarding the superiority or not of this novel protocol with
      corifollitropin alfa followed by hpHMG for the treatment of young poor ovarian responders
      fulfilling the Bologna criteria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently, the European Society of Human Reproduction and Embryology developed a new
      definition in order to select patients suitable for inclusion in future clinical trials as
      poor ovarian responders, the so-called &quot;Bologna criteria&quot;. However, a limited number of
      studies has been published to date including patients with poor ovarian response according to
      the &quot;Bologna criteria&quot;, whereas no randomized trial is published or ongoing for this
      population.

      Preliminary reports in &quot;Bologna poor responders&quot; highlight the limited prospects for these
      women. Natural cycle IVF has been shown to result in disappointingly low live birth rates,
      regardless of patients' age and ovarian stimulation with widely accepted treatment
      modalities, e.g. short agonist protocol, did not appear demonstrate substantial benefits.

      Nonetheless, despite the disappointing results from the vast majority of the preliminary
      studies in this population, a recent pilot study by our group has shown that a specific
      protocol may indeed be a promising option for women of younger age fulfilling the &quot;Bologna
      criteria&quot;. Corifollitropin alfa followed by highly purified hMG in an antagonist protocol
      demonstrated an ongoing pregnancy rate of 28% in women &lt;40years, strongly suggesting the
      conduction of a future randomized trial testing this novel treatment protocol
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy</measure>
    <time_frame>9-10 weeks of gestation</time_frame>
    <description>The presence of intrauterine gestational sac with an embryonic pole demonstrating cardiac activity at 9-10 weeks of gestation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy</measure>
    <time_frame>7 weeks of gestation</time_frame>
    <description>The presence of intrauterine gestational sac at 7 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy</measure>
    <time_frame>2 weeks after embryo transfer</time_frame>
    <description>Positive pregnancy test 2 weeks after embryo transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes retrieved</measure>
    <time_frame>9 -20 days from initiation of ovarian stimulation</time_frame>
    <description>The outcome will be evaluated on the day of oocyte retrieval</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cycle cancellation due to poor ovarian response</measure>
    <time_frame>Day 8-10 of ovarian stimulation</time_frame>
    <description>Number of cycles cancelled due to monofollicular or no follicular development</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of cycles reaching the stage of embryo transfer</measure>
    <time_frame>9 -20 days from initiation of ovarian stimulation</time_frame>
    <description>The outcome will be evaluated 3 days after oocyte retrieval</description>
  </other_outcome>
  <other_outcome>
    <measure>Number and quality of embryos</measure>
    <time_frame>Day of embryo transfer</time_frame>
    <description>3 days after oocyte retrieval</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of cycles with frozen supernumerary embryos</measure>
    <time_frame>9 -20 days from initiation of ovarian stimulation</time_frame>
    <description>The outcome will be evaluated 5 days after oocyte retrieval or 2-3 days after embryo transfer in case of an embryo transfer</description>
  </other_outcome>
  <other_outcome>
    <measure>Endocrine parameters (LH,FSH, E2, Progesterone) during ovarian stimulation</measure>
    <time_frame>Days 1,6,8,10 of stimulation and day of ovulation triggering</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cycle cancellation due to serious adverse effects of medication</measure>
    <time_frame>20-25 days after initiation of stimulation</time_frame>
    <description>20-25 days after the initiation of ovarian stimulation all patients (cycles) will be monitored for the occurence of any adverse effect and cycle cancellation(during ovarian stimulation) due to a serious adverse effect from medication</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Infertility</condition>
  <condition>Poor Ovarian Response</condition>
  <arm_group>
    <arm_group_label>Corifollitropin alfa followed by hpHMG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>recombinant FSH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corifollitropin alfa</intervention_name>
    <description>Corifollitropin alfa 150μg on day 2 of the menstrual cycle (stimulation day 1)</description>
    <arm_group_label>Corifollitropin alfa followed by hpHMG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant FSH</intervention_name>
    <description>recombinant FSH 300IU/daily from day 2 of the cycle (stimulation day 8)until day of ovulation triggering</description>
    <arm_group_label>recombinant FSH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganirelix</intervention_name>
    <description>Ganirelix 0.25mg/daily from day 7 of the cycle(stimulation day 6) until day of ovulation triggering</description>
    <arm_group_label>Corifollitropin alfa followed by hpHMG</arm_group_label>
    <arm_group_label>recombinant FSH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hp HMG</intervention_name>
    <description>hp HMG 300IU/daily from day 9 of the cycle (stimulation day 8)until day of ovulation triggering</description>
    <arm_group_label>Corifollitropin alfa followed by hpHMG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age less than 40 years

          -  Fulfillment of the &quot;Bologna criteria&quot; for poor ovarian response.

        Based on inclusion criteria two patients' categories are eligible:

          1. Women &lt; 40 years old AND ≤3 oocytes in one of the previous cycles AND (Antral follicle
             count &lt;7 or antimullerian hormone serum values &lt;1.1 ng/ml)

          2. Women &lt;40 years old and ≤3 oocytes in two the previous cycles with maximum ovarian
             stimulation

        In addition women less than 40 years old will be considered eligible if they had undergone
        previous ovarian surgery or chemotherapy (risk factors for poor ovarian response) and have
        an AMH&lt;1.1ng/ml or an AFC&lt;7, as suggested by the Bologna criteria

        Exclusion Criteria:

          -  Uterine abnormalities

          -  Recent history of any current untreated endocrine abnormality

          -  Unilateral or bilateral hydrosalpinx (visible on transvaginal ultrasound, unless
             clipped)

          -  Contraindications for the use of gonadotropins

          -  Recent history of severe disease requiring regular treatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikolaos P Polyzos, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Medicine and Pharmacy of Ho Chi Minh City</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Vietnam</country>
  </location_countries>
  <removed_countries>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Spain</country>
  </removed_countries>
  <reference>
    <citation>Polyzos NP, De Vos M, Corona R, Vloeberghs V, Ortega-Hrepich C, Stoop D, Tournaye H. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study. Hum Reprod. 2013 May;28(5):1254-60. doi: 10.1093/humrep/det045. Epub 2013 Feb 26.</citation>
    <PMID>23442756</PMID>
  </reference>
  <reference>
    <citation>Polyzos NP, Devos M, Humaidan P, Stoop D, Ortega-Hrepich C, Devroey P, Tournaye H. Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: an observational pilot study. Fertil Steril. 2013 Feb;99(2):422-6. doi: 10.1016/j.fertnstert.2012.09.043. Epub 2012 Oct 16.</citation>
    <PMID>23084565</PMID>
  </reference>
  <reference>
    <citation>Polyzos NP, Blockeel C, Verpoest W, De Vos M, Stoop D, Vloeberghs V, Camus M, Devroey P, Tournaye H. Live birth rates following natural cycle IVF in women with poor ovarian response according to the Bologna criteria. Hum Reprod. 2012 Dec;27(12):3481-6. doi: 10.1093/humrep/des318. Epub 2012 Aug 30.</citation>
    <PMID>22940767</PMID>
  </reference>
  <reference>
    <citation>Polyzos NP, Devroey P. A systematic review of randomized trials for the treatment of poor ovarian responders: is there any light at the end of the tunnel? Fertil Steril. 2011 Nov;96(5):1058-61.e7. doi: 10.1016/j.fertnstert.2011.09.048. Review.</citation>
    <PMID>22036048</PMID>
  </reference>
  <reference>
    <citation>Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011 Jul;26(7):1616-24. doi: 10.1093/humrep/der092. Epub 2011 Apr 19.</citation>
    <PMID>21505041</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2013</study_first_submitted>
  <study_first_submitted_qc>March 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2013</study_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Nikolaos P. Polyzos</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganirelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

